Total Payments
$18,719
2024 Payments
$1,029
Companies
47
Transactions
457
Medicare Patients
2,836
Medicare Billing
$516,106
Payment Breakdown by Category
Research$9,396 (50.2%)
Food & Beverage$7,924 (42.3%)
Travel$1,327 (7.1%)
Gifts$59.40 (0.3%)
Education$12.35 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9,396 | 2 | 50.2% |
| Food and Beverage | $7,924 | 444 | 42.3% |
| Travel and Lodging | $1,327 | 8 | 7.1% |
| Gift | $59.40 | 1 | 0.3% |
| Education | $12.35 | 2 | 0.1% |
Payments by Type
Research
$9,396
2 transactions
General
$9,323
455 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $9,396 | 2 | $0 (2020) |
| Medtronic MiniMed, Inc. | $1,539 | 23 | $0 (2020) |
| Novo Nordisk Inc | $803.99 | 51 | $0 (2024) |
| Lilly USA, LLC | $726.21 | 42 | $0 (2024) |
| Abbott Laboratories | $593.49 | 34 | $0 (2024) |
| Amgen Inc. | $565.46 | 27 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $542.95 | 33 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $526.82 | 33 | $0 (2022) |
| Tandem Diabetes Care, Inc. | $386.70 | 19 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $353.01 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,029 | 50 | Abbott Laboratories ($209.84) |
| 2023 | $1,371 | 72 | Abbott Laboratories ($245.27) |
| 2022 | $901.79 | 47 | Amgen Inc. ($165.24) |
| 2021 | $890.09 | 52 | VistaPharm, Inc. ($98.86) |
| 2020 | $1,602 | 50 | Eli Lilly and Company ($587.91) |
| 2019 | $9,604 | 45 | Eli Lilly and Company ($8,808) |
| 2018 | $2,261 | 67 | Medtronic MiniMed, Inc. ($1,431) |
| 2017 | $1,059 | 74 | SANOFI-AVENTIS U.S. LLC ($261.36) |
All Payment Transactions
457 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Ascendis Pharma Inc | — | Food and Beverage | In-kind items and services | $13.34 | General |
| 12/11/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: VACCINES | ||||||
| 12/10/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Endocrinology | ||||||
| 12/03/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: Endocrinology | ||||||
| 11/27/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: Endocrinology | ||||||
| 11/25/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Diabetes Care | ||||||
| 11/19/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/28/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Diabetes Care | ||||||
| 10/23/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $24.71 | General |
| 10/23/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Endocrinology | ||||||
| 10/22/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $10.87 | General |
| 10/18/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: Diabetes Care | ||||||
| 10/01/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: Durable Pump | ||||||
| 09/24/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Endocrinology | ||||||
| 09/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Diabetes | ||||||
| 09/16/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $23.74 | General |
| Category: Endocrinology | ||||||
| 09/04/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/03/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Obesity | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/27/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/22/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: Diabetes Care | ||||||
| 08/20/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: Diabetes | ||||||
| 08/13/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/06/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Durable Pump | ||||||
| 07/31/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $26.70 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES | Eli Lilly and Company | $9,396 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 945 | 6,182 | $585,067 | $197,349 |
| 2022 | 9 | 698 | 3,906 | $393,109 | $125,997 |
| 2021 | 7 | 590 | 2,830 | $330,780 | $104,783 |
| 2020 | 8 | 603 | 2,653 | $265,421 | $87,976 |
Total Patients
2,836
Total Services
15,571
Medicare Billing
$516,106
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 475 | 1,046 | $349,908 | $91,456 | 26.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 53 | 4,620 | $152,318 | $85,240 | 56.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 136 | 136 | $58,748 | $14,470 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 44 | 48 | $11,302 | $2,574 | 22.8% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 103 | 163 | $3,594 | $1,546 | 43.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 67 | 98 | $5,292 | $965.62 | 18.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 30 | 31 | $2,838 | $739.48 | 26.1% |
| J0834 | Injection, cosyntropin, 0.25 mg | Office | 2023 | 13 | 14 | $796.32 | $257.58 | 32.3% |
| 82947 | Blood glucose (sugar) level | Office | 2023 | 24 | 26 | $271.96 | $100.10 | 36.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 378 | 717 | $239,851 | $61,109 | 25.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 38 | 2,881 | $91,587 | $49,022 | 53.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 88 | 88 | $38,013 | $10,140 | 26.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 43 | $10,124 | $2,326 | 23.0% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 21 | 21 | $6,330 | $1,371 | 21.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 26 | 32 | $2,929 | $856.32 | 29.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 42 | 54 | $2,916 | $593.09 | 20.3% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 48 | 54 | $1,191 | $518.97 | 43.6% |
| 82947 | Blood glucose (sugar) level | Office | 2022 | 14 | 16 | $167.36 | $61.60 | 36.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 356 | 678 | $222,716 | $59,788 | 26.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 22 | 1,920 | $59,449 | $31,734 | 53.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 52 | 52 | $22,304 | $6,465 | 29.0% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 40 | 41 | $12,309 | $3,345 | 27.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 46 | 47 | $10,891 | $2,592 | 23.8% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 47 | 55 | $1,213 | $534.05 | 44.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 27 | 37 | $1,898 | $324.22 | 17.1% |
About Dr. Travis Monchamp, MD
Dr. Travis Monchamp, MD is a Nuclear Imaging & Therapy healthcare provider based in Bend, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396776324.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Travis Monchamp, MD has received a total of $18,719 in payments from pharmaceutical and medical device companies, with $1,029 received in 2024. These payments were reported across 457 transactions from 47 companies. The most common payment nature is "" ($9,396).
As a Medicare-enrolled provider, Monchamp has provided services to 2,836 Medicare beneficiaries, totaling 15,571 services with total Medicare billing of $516,106. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Imaging & Therapy
- Other Specialties Diabetes & Metabolism
- Location Bend, OR
- Active Since 07/06/2006
- Last Updated 02/18/2020
- Taxonomy Code 207UN0902X
- Entity Type Individual
- NPI Number 1396776324
Products in Payments
- Minimed 670G System (Device) $1,501
- FREESTYLE LIBRE 3 (Device) $455.11
- FARXIGA (Drug) $451.02
- AFREZZA (Drug) $301.31
- TRULICITY (Drug) $264.50
- Dexcom G6 Transmitter (Medical Supply) $257.47
- TOUJEO (Drug) $244.98
- Ozempic (Drug) $242.42
- EVENITY (Biological) $241.42
- Strensiq (Drug) $230.98
- Repatha (Biological) $197.93
- INVOKANA (Drug) $196.72
- Kerendia (Drug) $188.78
- t-slim insulin pump (Device) $183.54
- TEPEZZA (Drug) $182.97
- t:slim X2 Insulin Pump with Control-IQ (Device) $178.59
- SOLIQUA (Drug) $145.07
- HUMULIN (Drug) $142.74
- Vascepa (Drug) $140.27
- MOUNJARO (Drug) $129.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.